Forte Biosciences (FBRX) Total Current Liabilities (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Total Current Liabilities of $23.6 million for Q1 2026, up 161.81% year-over-year from $9.0 million in Q1 2025, and up 13.96% quarter-over-quarter from $20.8 million in Q4 2025.
Forte Biosciences (FBRX) Total Current Liabilities (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Total Current Liabilities for 11 consecutive years, with $23.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 161.81% year-over-year to $23.6 million; the TTM figure through Mar 2026 stood at $23.6 million (up 161.81% YoY), while the FY2025 annual figure was $20.8 million, up 128.51% from the prior year.
- Total Current Liabilities grew to $23.6 million in Q1 2026 per FBRX's latest filing, from $20.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $23.6 million in Q1 2026 and bottomed at $1.3 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $7.9 million across 5 years, with a median of $7.5 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 49.19% — and 2023, when it jumped 316.39%.
- Forte Biosciences' Total Current Liabilities stood at $3.2 million in 2022, then climbed by 15.32% to $3.7 million in 2023, then soared by 147.71% to $9.1 million in 2024, then jumped by 128.51% to $20.8 million in 2025, then grew by 13.96% to $23.6 million in 2026.
- Business Quant data shows FBRX's Total Current Liabilities at $23.6 million in Q1 2026, $20.8 million in Q4 2025, and $13.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 20.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.29 Mn |
| Mar 31, 2026 | 23.65 Mn |
| Dec 31, 2025 | 20.75 Mn |
| Sep 30, 2025 | 12.99 Mn |
| Jun 30, 2025 | 9.17 Mn |
| Mar 31, 2025 | 9.03 Mn |
| Dec 31, 2024 | 9.08 Mn |
| Sep 30, 2024 | 8.58 Mn |
| Jun 30, 2024 | 9.12 Mn |
| Mar 31, 2024 | 3.33 Mn |
| Dec 31, 2023 | 3.67 Mn |
| Sep 30, 2023 | 7.47 Mn |
| Jun 30, 2023 | 6.30 Mn |
| Mar 31, 2023 | 3.76 Mn |
| Dec 31, 2022 | 3.18 Mn |
| Sep 30, 2022 | 2.29 Mn |
| Jun 30, 2022 | 1.51 Mn |
| Mar 31, 2022 | 1.26 Mn |
| Dec 31, 2021 | 1.76 Mn |
| Sep 30, 2021 | 3.74 Mn |